Russian health policies and inaction risk 'super-resistant' TB warn MSF

Michael Carter
Published: 23 January 2004

Inaction by Russian health authorities could mean that super-resistant strains of tuberculosis (TB) emerge in the country, according to a letter from Medecins sans Frontiieres (MSF) published in the January 17th edition of The Lancet.

MSF is calling on international bodies such as the World Health Organisation (WHO) and the World Bank to ensure that Russian TB control comes up to internationally agreed standards, warning that unless such action is taken any donations to fight TB in Russia could do more harm than good.

From 1996 to September 2003 MSF worked in Siberian prisons, with the agreement of the penal authorities, to provide WHO-led directly observed (DOTS) TB therapy. Approximately 22% of new TB, and 40% of re-treatment cases treated by MSF doctors involved multi-drug resistant tuberculosis (MDR-TB). Expensive treatment options involving costly second-line TB drugs for up to two years were not available to the MSF physicians.

In order to obtain quality therapy capable of achieving a cure, MSF and the regional Russian authorities submitted an application to the Green Light Committee, which was accepted and would have enabled the aid agency to provide recognised MDR-TB treatment to 150 Siberian prisoners.

The Russian Health Ministry rejected MSF’s application to use the drugs, however, even though the treatment regimens met internationally agreed standards, stating that the proposed treatments contradicted the guidelines of the Russian Pharmaceutical Committee. What’s more, the Russian health authorities classified the treatment regimen as “experimental” and therefore forbidden under penal law.

Russian drug legislation forbids the use of some second-line TB drugs. This legislation is completely out of step with recognised international treatment principles on the drugs to be used for MDR-TB and the duration of therapy.

MSF say that “to comply with the existing drug legislation, we were effectively being asked to implement a treatment strategy for MDR-TB that contradicts the basic treatment principles outlined by WHO.” Therefore, MSF pulled out of Siberia in September 2003.

The difficulties encountered by MSF in Siberia do not, however, appear to be a one-off. In 2003 Russian health authorities published protocols for Russian doctors for standard and MDR-TB therapy. These protocols, approved by WHO, should have meant that Russian TB control incorporated international treatment standards, an essential requirement for a substantial World Bank loan for TB control.

”We now know”, say MSF, “that, at least for MDR-TB these standards are not being met.” This means that for about a year some Russian regions have been using second-line TB drugs without “clear guidelines, appropriate infrastructure, trained personnel, and with non-existent follow-up for released patients under treatment.” MSF warns that this means “an increased risk of creating super resistant TB” and calls on WHO and the World Bank to take action.

”Future control of TB in Russia is in the balance” conclude MSF, adding “the donor community runs the risk of doing more harm than good.”

Further information on this website

Tuberculosis - overview

Tuberculosis, public health and the need for ARVs - news story

AIDS Treatment Update, January 2003 - includes information on the interaction between TB and HIV in Russian prisons

Reference

Lafontaine D et al. Treatment for multidrug-resistant tuberculosis in Russian prisons. The Lancet 363, 246 – 247, 2004.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.